drugset
drugset / Trial / NCT02392039

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

NCT02392039 ↗

Phase 0 Terminated 1 enrolled M.D. Anderson Cancer Center Amgen · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The goal of this clinical research study is to learn if loratadine can control bone pain caused by pegfilgrastim (a drug given after chemotherapy to help raise white blood cell counts).

Timeline

Start
2015-12-14
Primary completion
2018-04-04
Completion
2018-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Loratadine Small molecule 10 mg Oral
Background Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous

Indications

lymphoma